Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib induction followed by STUPP regimen in newly diagnosed glioblastoma with postoperative residual
ChiCTR2500113855Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in glioblastoma (GBM), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started Dec 2025; status: recruiting.
02
Drugs
anlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2500113855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113855.